Dostinex tab is a drug used to treat hyperprolactinemia, a condition in which high levels of prolactin - a substance that helps breastfeeding mothers. Too much prolactin can cause pain in both men, and women who are not breastfeeding.
Dostinex tab, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic and Parkinsonian syndrome. Cabergoline has a potent agonist activity on dopamine D2 receptors.
Dostinex tab stimulates centrally-located dopaminergic receptors that cause several pharmacologic effects. Five dopamine receptor factors from both dopaminergic subfamilies were identified. The Dopaminergic D1 receptor subfamily contains D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily contains D2, D3 and D4 subreceptors, which are involved in the development of movement symptoms. Thus, agonist activity specific to D2 subfamily receptors, mainly D2 and D3 receptor subtypes, is the primary target of dopaminergic antiparkinsonian agents. It is thought that feedback on Posynaptic D2 is responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 recognizes neuroprotective effects. This semisynthetic ergot derivative exhibits strong agonist activity at dopamine D2- and D3-receptors. It also showed: agonist activity (in the sense of reduced coordination) of 5-hydroxytryptamine (5-HT) 2B, 5-HT2A, 5-HT1D, dopamine D4, 5-HT1A, dopamine D1, 5-HT1B and 5-HT2C. . receptors and antagonist functions of α2B, α2A, and α2C receptors. Parkinsonian syndrome manifests during approximately 80% of dopaminergic activity in nigrostriatal pathways of the brain. As this striatum is involved in normal movement of the joint muscles (e.g., movement, balance, walking), loss of activity may lead to dystonia (muscle spasms). , Parkinsonism (including symptoms of bradykinesia, tremors, stiffness, and disturbances), akathesia (restlessness), tardive dyskinesia (regular exercise may be associated with long-term dopaminergic activity), and neuroleptic malignant syndrome, which occur when complete blockage of nigrostriatal dopamine. . occurs. High dopaminergic activity in the mesolimbic brain pathway leads to visualization and forgetfulness; The side effects of dopamine agonists are a hallmark in schizophrenia patients with previous experience in this area of the brain. The expected effects of dopamine agonists are also due to 5-HT2A agonism. The tuberoinfundibular tract of the brain begins in the hypothalamus and ends in the pituitary gland. In these methods, dopamine inhibits lactotrophs in the anterior pituitary by prolactin secretion. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion.